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Objective The aim of this study was to estimate the field efficacy of the first routine programme for the prevention of mother-to-
child transmission (PMTCT) of human immunodeficiency virus (HIV) initiated in South Africa, in the subdistrict of Khayelitsha.
Methods A consecutive sample of 658 mother–infant pairs, identified from the PMTCT register from 1 March to 30 November 
2003, were identified for enrolment in this study. Details of the regimen received were established and HIV status of the infants 
at between 6 and 10 weeks of age was determined by qualitative DNA polymerase chain reaction. Zidovudine (AZT) was provided 
antenatally from week 34 of gestation and during labour. Infant formula milk was offered to mothers who chose not to breastfeed. 
The protocol was amended in July 2003 such that women who had received < 2 weeks of treatment with AZT were given a single 
dose of nevirapine (NVP) at the onset of labour, and the infant received a weight-adjusted dose of NVP within 72 h of delivery.
Results Of the 535 mother–infant pairs (81%) eventually included in the study, 410 (77%) received an effective PMTCT intervention 
according to the protocol. The rate of transmission of HIV from mother to child was 8.8% (95% confidence interval (CI), 6.2–10.9).  
A maternal age of > 25 years was the only significant independent risk factor for transmission (odds ratio, 2.12; 95% CI, 1.14–4.07).
Conclusion The results of this study demonstrate the feasibility and effectiveness of a large-scale PMTCT programme in an urban 
public-sector setting.
Keywords HIV infections/transmission/prevention and control/drug therapy; Disease transmission, Vertical/prevention and control; 
Zidovudine/therapeutic use; Nevirapine/therapeutic use; Breast feeding/adverse effects; Bottle feeding; Pregnancy; Outcome and 
process assessment (Health care); National health programs; Cross-sectional studies; South Africa (source: MeSH, NLM).
Mots clés Infection à VIH/transmission/prévention et contrôle/chimiothérapie; Transmission verticale maladie/prévention et contrôle; 
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INSERM).
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Introduction
Mother-to-child transmission (MTCT) of human immuno- 
deficiency virus (HIV) is the most significant route of HIV infec-
tion in children. In South Africa, the risk of vertical transmission 
from HIV-infected mothers to their infants is estimated to be 
between 19% and 36%, depending on whether or not the child 
is breastfed (1). The prevalence of infection with HIV among 
expectant mothers attending public-sector clinics was 27.9% 
in 2003 (2), and an estimated 75 000 infants would be born 
infected with HIV-1 in South Africa each year in the absence of 
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programmes to reduce the risk of vertical transmission of HIV. 
International and local experience has shown that the provision 
of antiretroviral chemoprophylaxis and replacement feeding 
can cause a dramatic reduction in the risk of transmission from 
mother to infant in resource-constrained settings (3–8).
In 1999, the Department of Health of the Western Cape 
initiated the first pilot programme for the prevention of mother-
to-child transmission (PMTCT) in South Africa (9), based on 
evidence from similar programmes elsewhere in the world that 
showed a reduction in MTCT of 50% (3). Antenatally, this 
included voluntary counselling and testing, and the provision 
of zidovudine (AZT) at a dose of 300 mg given twice per day 
from week 36 of gestation until labour. In labour, mothers re-
ceived 300 mg of AZT every 3 h until delivery. Infant formula 
(replacement feeding) was offered for 9 months to mothers who 
chose not to breastfeed, after which the HIV status of the child 
was determined. Those children with a positive HIV test at age 
9 months were re-tested at age 18 months. After delivery, women 
attended one of the eight local authority clinics weekly, or every 
2 weeks, for 9 months. Support groups were an integral part of 
the services offered, both antenatally and postnatally.
The initial evolution of the programme has been described 
previously (9), including the move to earlier antenatal initiation 
of AZT therapy at week 34 of gestation in order to ensure that 
enrolled mothers received > 2 weeks of AZT therapy before 
delivery. Recent guidelines from WHO recommend that AZT 
should be provided from week 28 of gestation, where resources 
permit (10).
On the basis of the results of trials on the efficacy of 
PMTCT programmes based on peripartum therapy with 
nevirapine (NVP), the Province of the Western Cape and the 
National Department of Health subsequently developed NVP-
based protocols for the expansion of PMTCT services. The 
Khayelitsha district continued, however, to provide a PMTCT 
intervention based on a short course of treatment with AZT.
Between January 1999 and December 2003, 37 223 preg-
nant women registered with antenatal health-care services in 
Khayelitsha; 31 528 (84%) of these women were tested for 
HIV and 7043 (22.3%) were identified as being infected. The 
proportion of women testing positive for HIV increased from 
15.4% in 1999 to 25.9% in 2003, consistent with estimates 
from district antenatal surveys (11). In 2003, the rate of ac-
ceptance for voluntary counselling and testing had further 
improved to attain 97% of the 7314 women presenting for 
first antenatal visits.
The determination of HIV status in children born to 
mothers participating in the PMTCT programme previously re-
lied on testing for anti-HIV antibodies, performed between ages 
9 and 18 months, by which time a high proportion (30–40%) 
of children were lost to follow-up. Of the 1732 babies tested 
by the end of 2002, 12.5% tested positive for HIV.
Although the efficacy of PMTCT regimens based on a 
short course of treatment with AZT has been established in 
clinical trials (3, 5, 12), the effectiveness of such regimens in a 
large-scale programme integrated into routine antenatal and ob-
stetric health-care services has not been accurately demonstrated 
in the South African setting. A recent local study reported on 
the operational effectiveness of a NVP-based regimen (13).
By 2003, the PMTCT programme in the Western Cape 
covered all districts in the province, as a result of the expansion 
of the NVP-based protocol. The protocol in Khayelitsha was 
Table 1. Profile of mothers and infants enrolled in the study
Parameter Value 
Number of children tested 535
Median age of mother (years) (IQR)  26  (23–29)
Median age of child when tested (weeks) (IQRa)  6.57  (6.14–10.14)
Proportion of deliveries by Caesarian (95% CIb)c 0.23  (0.20–0.27)
Proportion of deliveries in hospital (95% CI) 0.52  (0.48–0.56)
Number of patients reporting mixed feedingc 4
a  IQR = intraquartile range.
b  CI = confidence interval.
c  n = 533 owing to unavailability of data.
amended in July 2003, midway through the study, to allow 
women who had received < 2 weeks of antenatal treatment with 
AZT to follow the NVP-based protocol, i.e. a single dose of 
200 mg of NVP to the mother at the onset of labour, and a 
weight-adjusted dose to the infant within 72 h of delivery.
This study aimed to estimate the field efficacy of the 
PMTCT programme in Khayelitsha, and to provide details on 
the antiretroviral regimens received by mothers and infants.
Methods
This was a cross-sectional study in which the primary out-
come was the HIV-status of infants aged 6–10 weeks. The 
study population was all mothers and infants enrolled in the 
Khayelitsha PMTCT programme and followed in the three 
largest local authority clinics, which account for > 75% of all 
postnatal follow-up related to the PMTCT programme in the 
district. A sample size of 500 mother–infant pairs was selected 
in order to provide a point estimate of transmission, with a 95% 
confidence interval (CI) of 6%, premised on an anticipated risk 
of transmission of 9%.
Using the clinic registers, all infants enrolled in the 
PMTCT programme in the three clinics were identified. At age 
6 weeks, after pre-test counselling by the facility-based counsel-
lors and obtaining written consent from the mother for the HIV 
test, 50 μl of blood was drawn from the heel of each infant and 
divided among three capillary tubes containing ethylenediami-
netetraacetic acid (EDTA). Specimens were transported daily 
to the Department of Virology at the University of Cape Town, 
where tests for HIV-1 were performed based on qualitative 
DNA polymerase chain reaction (PCR) (AMPLICOR®HIV-1 
DNA test, version 1.5; Roche). All mothers were interviewed 
to determine the feeding status of their infant from birth until 
the date of the interview, the respective number of doses of 
antiretroviral therapy received by the mother and infant, and 
the place and mode of delivery. Primary clinical records were 
not reviewed and there was no record of the extent of advance-
ment of disease attributable to HIV in the mother during 
pregnancy. Mothers were given the option of receiving the 
test result with post-test counselling. The majority of mothers 
received the result within 2 weeks of testing.
Statistical analyses were done using STATA™ (Stata Sta-
tistical Software: Release 8, College Station, TX: Stata Corpora-
tion LP). Transmission proportions were described with exact 
binomial 95% CI. Risk factors for transmission were assessed 
by multivariate logistic regression.
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Results
A total of 658 mothers were registered on the PMTCT pro-
gramme from 1 April to 30 November 2003, and 535 mother–in-
fant pairs were enrolled into the study (Table 1). This gives an 
overall response rate of 81%. An attempt was made to locate 
the 123 remaining children: 2 out of the 36 infants who could 
be traced had died, 25 had been transferred to other clinics in 
Cape Town or to the Eastern Cape and 9 subsequently returned 
to the clinics after absences of various lengths of time. The 
remaining non-responders (87) could not be traced due to 
insufficient contact information in the facility records.
Half the infants (278) in the study were delivered in hos-
pital, and 23% (124) of all infants were delivered by Caesarean 
section. Four women (< 1%) reported giving mixed feeding for 
between 1 and 18 days after delivery, with the rest reporting 
exclusive formula feeding.
Fifty-three percent of mothers (281) reported receiving 
at least 2 weeks of antenatal treatment with AZT in addi-
tion to AZT therapy during labour (Table 2). An additional 
24% (129) of mothers and infants received the appropriate 
NVP-based back-up regimen for mothers who had received 
insufficient AZT therapy before delivery. Thus 77% of women 
(410) received the correct regimen according to the policy at 
the time. The remaining 23% of mothers and infants (125) 
Table 2. Number of mother–infant pairs receiving each PMTCT regimen
Antenatal AZT therapy receiveda NVP therapy receiveda
 Mother and infant Mother only Infant only None Total
Antenatal and in labour 18 10 13 240  281b
Antenatal only 27 16 4 30 77 c
Labour only 9 2 4 8 23
< 14 days of antenatal AZT therapy 16 5 4 6 31d
None 77 20 9 17 123
Total 147 53 34 301 535
a  Figures in bold type reflect treatment exactly in accordance with the protocol. Figures in italic type reflect treatment that at minimum comprised a complete  
 regimen according to the protocol.
b  Median, four weekly packs of AZT were received by the mother (IQR, 3–6).
c  Median, three weekly packs of AZT were received by the mother (IQR, 2–5).
d  A single weekly pack of AZT was received by the mother.
received non-standard combinations of the two regimens, in-
cluding 3% (17) who reported not receiving any antiretrovirals. 
The median number of weeks of antenatal therapy with AZT 
received by those mothers who received AZT antenatally was 4 
(intraquartile range (IQR, 3–6). The median number of doses 
of AZT given during labour was 3 (IQR, 2–5) in those mothers 
who received AZT during labour. Of the infants tested, 181 
received neonatal prophylaxis with NVP.
Of the infants tested for HIV (535), 8.8% (47) tested 
positive (95% CI, 6.2–10.9%). The median age of children 
when the PCR test was done was 6.6 weeks (IQR, 6.1–10.1). 
The majority of women (513; 96%) elected to receive the PCR 
test result.
Although the study was not powered to detect differences 
in transmission based on risk factors or the regimen received, 
a multivariate analysis of the impact of a number of factors on 
transmission (Table 3) revealed that women aged > 25 years 
were more likely to transmit HIV to their infants.
Discussion
The majority of pregnant women in Khayelitsha accept HIV 
testing during pregnancy and are prepared to join the PMTCT 
programme. The high rates of acceptance for testing and subse-
quent enrolment are key to the effectiveness of the programme. 
Table 3. Risk of transmission (by regimen) and odds of transmission (by risk factor)
Category of antiretroviral treatment n % positive for HIVa 95% CIb
Overall rate of transmission 535 8.8 6.2–10.9
Short course of AZTc therapy as per protocol, no NVPd therapy 240 8.8 5.5–13.1
Short course of NVP therapy as per protocol, no AZT therapy 93 7.5 3.1–14.9
Either regimen as per protocol 333 8.4 5.7–11.9
Multivariate odds ratio of transmission (n = 535) Odds ratio P 95% CI
Either regimen as per protocol 0.85 0.917 0.46–1.58
Caesarian section 0.85 0.663 0.41–1.77
Maternal age > 25 years 2.15 0.019 1.14–4.08
a  HIV = human immunodeficiency virus.
b  Confidence interval.
c  AZT = zidovudine.
d  NVP = nevirapine.
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A number of studies in Africa have demonstrated the feasibility 
of PMTCT programmes in routine settings, but generally re-
port a high rate of attrition between being offered testing and 
subsequent enrolment in the programme (14–16).
More than 50% of women were referred to higher levels 
of care, either antenatally or during labour, reflecting an increase 
over previous years, and 23% (123) of all infants were delivered 
by Caesarian section. This could be due in part to the fact that 
more pregnant women are being referred for specialized care as a 
consequence of HIV infection, as good referral services exist.
The overall rate of transmission in this study was < 10%. 
This estimate falls within a range consistent with data from 
trials in which the same regimens were applied (3, 7, 17). This 
reflects the effectiveness of the PMTCT programme delivered 
within routine health-care services. Owing to the high uptake 
of replacement feeding, it is unlikely that these estimates would 
differ if measured in older children. The estimates for mode 
of feeding are consistent with those previously reported from 
this programme in Khayelitsha (18).
The association between maternal age and MTCT could 
be a function of the advancement of the disease. It has been 
shown previously that the more advanced the disease, as mea-
sured by CD4+ lymphocyte count, the higher the rate of vertical 
transmission (19).
In addition to the protocol change midway through the 
study, there are a number of other limitations to this study. 
The non-response rate of 19% is a concern and (although lower 
than that reported previously) may still result in some selection 
bias, as those children whom it was not possible to locate may 
have died as a result of infection with HIV. It was not possible 
to review the primary obstetric records. There is therefore also 
the potential for information bias in ascertaining the inter-
ventions received, as this relied on patient recall rather than on 
primary clinical records.
The operational changes to the programme during the 
study provided a unique study opportunity. At short notice, 
staff were able to provide a back-up regimen for a large propor-
tion of mothers who had not received the primary intervention 
for an adequate duration. If PMTCT interventions include 
antenatal antiretroviral therapy for 4–12 weeks, many women 
may present for delivery without having received adequate 
therapy. This study has demonstrated that a back-up strategy 
based on peripartum therapy with NVP can be effectively imple-
mented to address missed opportunities. The administration 
by clinical staff of NVP to the mother on admission in labour 
(as was the practice at the time of this study), rather than self- 
administration of a take-home dose, should increase the pre-
delivery uptake of antiretroviral therapy.
In this study, one-third of women presented for delivery 
having received AZT therapy for an inadequate duration, 
despite the earlier protocol adjustment to begin AZT therapy 
at week 34 of gestation. The current WHO guidelines on 
PMTCT protocols for resource-constrained settings stress the 
added benefit of beginning AZT at week 28 of gestation (10). It 
is clear from this study that this would not only further reduce 
the rate of transmission in those women receiving 10 or more 
weeks of AZT therapy, but would also ensure that a smaller 
proportion of women presented for delivery having received 
< 2 weeks of AZT therapy.
After this study was concluded, there was a further pro-
tocol change in Khayelitsha and elsewhere in the province such 
that in addition to antenatal treatment with AZT, mothers are 
now routinely given peripartum treatment with NVP and their 
infants now receive 7 days of treatment with AZT and a single 
dose of NVP. With this protocol it is anticipated that rates of 
transmission will decrease to < 5%, in line with results of trials 
elsewhere (12). It is now routine practice in the Western Cape 
to test infants participating in the PMTCT programme for HIV 
by PCR at age 14 weeks, and the initial results from Khayelitsha 
indicate that the vertical transmission rate is indeed falling. At 
the time of writing, the province is considering increasing the 
duration of antenatal therapy with AZT by providing AZT 
from week 28 of gestation. Although it appears that there are 
no studies in Africa that have reported on this regimen, data 
from a trial in Thailand suggest a rate of transmission of close 
to 2% (5). Operational research in this province could yield 
valuable information for PMTCT programmes in Africa.
The same study in Thailand has provided the first data 
on outcomes of post-PMTCT maternal treatment with anti-
retrovirals that has raised serious concerns about resistance to 
NVP (20). There are two approaches to minimize these risks. 
Firstly, there is early evidence to suggest that providing ad-
ditional antiretroviral therapy to post-partum mothers when 
their serum concentrations of NVP are falling may reduce the 
proportion of mothers who develop resistance to NVP (21). 
Secondly, mothers that are eligible for lifelong three-drug an-
tiretroviral therapy programmes can be started on combined 
antiretroviral therapy (cART) while they are pregnant, in line 
with WHO guidelines (10). With this in mind, routine testing 
for CD4+ lymphocyte count in mothers infected with HIV 
has been introduced as part of the PMTCT programme, with a 
view to referring eligible women for cART. There are also strong 
advocates for the provision of cART to all pregnant women in-
fected with HIV. All these approaches are premised on regimens 
that require that mothers receive treatment with antiretrovirals 
at least twice per day for some part of their pregnancy or of the 
postnatal period.
This study has demonstrated that complex regimens can 
be delivered effectively on a large scale within routine health-
care services, in areas with a high prevalence of infection with 
HIV. With simple amendments to the PMTCT programme 
described here, further reductions in the vertical transmission 
of HIV should be realized. Routine testing for HIV by PCR of 
all infants at age 14 weeks will ensure that these improvements 
are documented, that HIV-infected infants are managed earlier 
and that the quality of family counselling is improved.
Conclusion
The Khayelitsha PMTCT programme has entered its sixth 
year and the proportion of women opting to join remains 
high. A back-up strategy, using peripartum treatment with 
NVP for mothers receiving AZT therapy for an inadequate 
duration before delivery, was successfully implemented. The 
rate of transmission is low, at < 10%. These results corroborate 
those reported in Johannesburg at Coronation Hospital (13), 
and demonstrate the feasibility and effectiveness of a PMTCT 
programme within busy routine obstetric services in an urban 
primary health-care setting.  O
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Résumé
Efficacité du premier programme de prévention de la transmission mère-enfant du VIH, mené en Afrique 
du Sud à l’échelle du district
Objectif La présente étude vise à évaluer l’efficacité sur le terrain du 
premier programme de prévention systématique de la transmission de 
la mère à l’enfant (PTME) du virus de l’immunodéficience humaine, 
lancé dans le sous-district de Khayelitsha, en Afrique du Sud.
Méthodes Un échantillon consécutif de 658 couples mère-
nourrisson a été constitué à partir de l’analyse du registre de PTME 
du 1er mars au 30 novembre 2003, pour servir de support à l’étude. 
Les enquêteurs ont déterminé de manière précise l’alimentation 
reçue par le nourrisson et le statut VIH de celui-ci entre 6 et 10 
semaines par une recherche qualitative de l’ADN par PCR. Les mères 
ont reçu de la Zidovudine (AZT) pendant la période anténatale, 
à partir de la 34e semaine de grossesse et pendant le travail. Des 
préparations pour nourrissons ont été proposées aux mères ayant 
choisi de ne pas allaiter. En juillet 2003, les enquêteurs ont apporté 
au protocole une modification prévoyant l’administration au début 
du travail d’une dose unique de névirapine (NVP) aux femmes 
traitées pendant moins de 2 semaines à l’AZT et d’une dose de NVP 
déterminée en fonction du poids au nourrisson dans les 72 heures 
suivant l’accouchement.
Résultats Parmi les 535 couples mère-nourrisson (81 %) inclus en 
fin de compte dans l’étude, 410 (77 %) ont effectivement bénéficié 
d’une intervention de PTME conforme au protocole. Le taux de 
transmission du VIH de la mère à l’enfant était de 8,8 % [intervalle 
de confiance à 95 % (IC) : 6,2 - 10,9]. Le seul facteur de risque 
indépendant jouant un rôle important dans la transmission était 
un âge maternel supérieur à 25 ans (odds ratio : 2,12, intervalle 
de confiance à 95 % : 1,14 - 4,07).
Conclusion Les résultats de cette étude démontrent la faisabilité 
et l’efficacité d’un programme de PTME à grande échelle dans un 
centre de soins public et urbain.
Resumen
Eficacia del primer programa distrital de prevención de la transmisión del VIH de la madre al niño en 
Sudáfrica
Objetivo Estimar la eficacia sobre el terreno del primer programa 
sistemático de prevención de la transmisión de la madre al niño 
(PTMN) del virus de la inmunodeficiencia humana (VIH) iniciado 
en Sudáfrica, en el subdistrito de Khayelitsha.
Métodos Se reclutó para el estudio a una serie consecutiva de 
658 pares de madre y lactante, identificados mediante el registro 
de PTMN entre el 1 de marzo y el 30 de noviembre de 2003. Se 
establecieron los detalles del tratamiento administrado y se utilizó 
la PCR (reacción en cadena de la ADN-polimerasa) cualitativa para 
determinar la serología VIH de los lactantes entre las 6 y las 10 
semanas de edad. Se proporcionó zidovudina (AZT) prenatal a 
partir de la 34 semana de gestación y durante el parto. A las madres 
que decidieron no dar de mamar se les ofreció leche maternizada. 
El protocolo se modificó en julio de 2003 de manera que a las 
mujeres tratadas con AZT durante menos de 2 semanas se les 
administró una dosis única de nevirapina (NVP) al comienzo del 
parto, y el lactante recibía una dosis de NVP ajustada a su peso 
dentro de las primeras 72 horas tras el parto.
Resultados De los 535 pares de madre y lactante (81%) 
finalmente incluidos en el estudio, 410 (77%) recibieron una 
intervención eficaz de PTMN según el protocolo. La tasa de 
transmisión del VIH de madre a hijo fue del 8,8% (intervalo de 
confianza (IC) del 95%: 6,2-10,9). Una edad materna superior a 
25 años fue el único factor de riesgo de transmisión independiente 
y significativo (OR: 2,12; IC95%: 1,14-4,07).
Conclusión Los resultados de este estudio demuestran la 
viabilidad y la eficacia de un programa de PTMN a gran escala en 
un entorno urbano del sector público.
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